Comparative Pharmacology
Head-to-head clinical analysis: FLAREX versus MAXITROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAREX versus MAXITROL.
FLAREX vs MAXITROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that inhibits phospholipase A2 activity, reducing arachidonic acid release and subsequent production of prostaglandins and leukotrienes, thereby suppressing ocular inflammation.
Maxitrol is a combination of dexamethasone (corticosteroid), neomycin (aminoglycoside antibiotic), and polymyxin B (polymyxin antibiotic). Dexamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Neomycin binds to bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides.
1-2 drops in the conjunctival sac every hour during the day and every 2 hours at night initially; after response, reduce to 1 drop every 4 hours, then 1 drop 3-4 times daily. Ophthalmic suspension.
1-2 drops or 0.5-1 inch strip of ointment into the conjunctival sac every 4-6 hours; in severe cases, every 2-4 hours. Frequency may be reduced after improvement.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours (mean 1.3 hours) in adults. Due to rapid clearance, accumulation is minimal with topical ophthalmic dosing, but prolonged use may lead to systemic absorption and slightly extended half-life.
Neomycin: 2–3 h (topical) but prolonged in renal impairment. Polymyxin B: 6–7 h (topical). Dexamethasone: 3–4 h (topical). Clinical: systemic absorption minimal with intact epithelium; half-life may be prolonged with corneal abrasion or inflammation.
Primarily hepatic metabolism, with inactive metabolites excreted renally (approximately 60-80%) and fecally (20-40%). Less than 5% of unchanged drug appears in urine.
Renal: neomycin 30–50%; polymyxin B <1%; dexamethasone <1%. Fecal: neomycin >50% (unabsorbed); polymyxin B >99% (unabsorbed); dexamethasone <5%. Biliary: negligible for all components.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination